Targeting mitochondrial oxidative phosphorylation: lessons, advantages, and opportunities

In light of the disappointing termination of clinical trials with potent complex I inhibitors, such as IACS-010759, justification for oxidative phosphorylation inhibitors and mitochondrial targeting strategies has been called into question. Consideration of these agents’ potency, tissue selectivity...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:British journal of cancer Ročník 129; číslo 6; s. 897 - 899
Hlavní autoři: Machado, Nicole D, Heather, Lisa C, Harris, Adrian L, Higgins, Geoff S
Médium: Journal Article
Jazyk:angličtina
Vydáno: England Nature Publishing Group 05.10.2023
Témata:
Clinical trials
Electron transport chain
Humans
Inhibitor drugs
Medical research
Mitochondria - metabolism
Oxidative Phosphorylation
Phosphorylation
Targeted cancer therapy
Toxicity
ISSN:0007-0920, 1532-1827, 1532-1827
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:In light of the disappointing termination of clinical trials with potent complex I inhibitors, such as IACS-010759, justification for oxidative phosphorylation inhibitors and mitochondrial targeting strategies has been called into question. Consideration of these agents’ potency, tissue selectivity and toxicity demonstrate what lessons can be learned from this failure and where new opportunities lie.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:0007-0920
1532-1827
1532-1827
DOI:10.1038/s41416-023-02394-9